ArticleThe Journal of experimental medicine1997
CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.
Article in The Journal of experimental medicine, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 118 citations in OpenAlex.
- Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics.Journal of advanced research · 2026Review
- Enhancing Antitumor Efficacy of MUC1 mRNA Nano-Vaccine by CTLA-4 siRNA-Mediated Immune Checkpoint Modulation in Triple Negative Breast Cancer Mice Model.International journal of molecular sciences · 2025Article
- Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2023Review
- Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy.Science translational medicine · 2023Article
- Differential trafficking of ligands trogocytosed via CD28 versus CTLA4 promotes collective cellular control of co-stimulation.Nature communications · 2022Article
- Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies.Drug delivery and translational research · 2021Review
- Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges.Journal of nanobiotechnology · 2020Review
- Insights into CD8 T Cell Activation and Exhaustion from a Mouse Gammaherpesvirus Model.Viral immunology · 2020Review
- Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.Trends in pharmacological sciences · 2020Review
- A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.Cell research · 2018Article
- Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase.PloS one · 2014Article
- Ligation of cytotoxic T lymphocyte antigen-4 to T cell receptor inhibits T cell activation and directs differentiation into Foxp3+ regulatory T cells.The Journal of biological chemistry · 2012Article
- Cytotoxic T lymphocyte antigen-4 promoter -658CT gene polymorphism is associated with ulcerative colitis in Chinese patients.International journal of colorectal disease · 2009Article
- CD28/B7-mediated co-stimulation is critical for early control of murine cytomegalovirus infection.Viral immunology · 2009Article
- Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms.Endocrine reviews · 2008Review
- CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques.Blood · 2006Article
- CD80 and CD86 control antiviral CD8+ T-cell function and immune surveillance of murine gammaherpesvirus 68.Journal of virology · 2006Article
- Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy.The Journal of clinical investigation · 2001Article
- B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4.The Journal of clinical investigation · 2001Article
- Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
T cell costimulation, particularly by the B7 family members B7-1 and B7-2, plays a critical role in regulating T cell-mediated immunity. Two molecules on T cells, CD28 and CTLA-4, are known to bind to B7. It has been suggested that CD28-B7 interaction promotes T cell response, whereas B7-CTLA-4 interaction downregulates T cell clonal expansion. However, the proposed responses of individual receptors to B7 have not been verified directly. Here, we report that B7-1 promotes clonal expansion of CD28-deficient T cells, and that the CD28-independent costimulatory activity is mediated by CTLA-4, as it is completely blocked by intact and Fab of anti-CTLA-4 mAb. In addition, a mutant B7-1 molecule, B7W88 >A, which has lost binding to CD28 but retained significant CTLA-4 binding activity, promotes T cell clonal expansion. Furthermore, while presence of CD28 enhances T cell response to B7-1, such response is also completely blocked by anti-CTLA-4 mAb. Taken together, our results demonstrate that B7-CTLA-4 interaction promotes T cell clonal expansion, and that optimal T cell response to B7 is achieved when both CD28 and CTLA-4 interact with B7. These results establish an important function of CTLA-4 in promoting T cell activation, and suggest an alternative interpretation of the function of CTLA-4 in T cell activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.